why choose us

First received: February 16, 2023

Clinical Trial: ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Kidney Disease

Study Type: INTERVENTIONAL


Official Title: ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, R

Brief Summary: The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

Read more